Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 - Arix Bioscience

Close Navigation

About Strategy Team Portfolio Insights Media Contact

Overlay

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

3rd October 2022

Portfolio

This post references, or is about Aura. Find out more by clicking below

Video

Cambridge, USA

Useful Tools

Download, print or share this article

Print

Print Article Email

Email

Print

Share Article